HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

equiguard

suppresses androgen-dependent LNCaP prostate cancer cell proliferation by targeting cell cycle control via down regulation of the retinoblastoma protein Rb and induction of apoptosis via the release of cytochrome C
Networked: 5 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Experts

1. Hsieh, Tze-Chen: 4 articles (01/2008 - 04/2002)
2. Wu, Joseph M: 4 articles (01/2008 - 04/2002)
3. Lu, Xiaohua: 3 articles (12/2004 - 04/2002)
4. Guo, Junqiao: 2 articles (05/2003 - 04/2002)
5. Tian, Shou-fu: 1 article (09/2008)
6. Xiong, Pei-hua: 1 article (09/2008)
7. Gu, Mei-hua: 1 article (09/2008)
8. Zhang, Ling: 1 article (09/2008)
9. Chen, Ai-ping: 1 article (09/2008)
10. Darzynkiewicz, Zbigniew: 1 article (04/2002)

Related Diseases

1. Neoplasms (Cancer)
2. Carcinoma (Carcinomatosis)
3. Prostatic Neoplasms (Prostate Cancer)
4. Prostatism
5. Yang Deficiency (Xu, Yang)

Related Drugs and Biologics

1. Hormones
2. Plant Preparations (Preparation, Plant)
3. Prostate-Specific Antigen (Semenogelase)
4. Androgen Receptors (Androgen Receptor)
5. Cytochromes c (Cytochrome c)
6. Retinoblastoma Protein
7. Ethanol (Ethyl Alcohol)